Clinical trials

EndoPredict^® Breast Cancer Prognostic Test is actively involved in ongoing prospective clinical trials, all of which can be found on this page.

List of ongoing clinical trials

Title	Summary	Indication	Protocol number	Start date	Link to ClinicalTrials.gov page
RESCUE (Reaching For Evidence-Based Chemotherapy Use In Endocrine-Sensitive Breast Cancer)	Systematic assessment of survival data of patients who have been tested with EndoPredict®; prospective proof that patients with low risk classification by EndoPredict® (EPclin) can safely forgo chemotherapy and be treated with endocrine therapy alone.	Primary Invasive Breast Cancer ER positive tumor HER2 negative tumor	NCT03503799	July 17, 2018	Learn more
UNIRAD (Safety Study of Adding *** (EVE) to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy)	Randomized, Double Blind, Multicentric Phase III Trial Evaluating the Safety and Benefit of Adding *** (EVE) to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer Who Remain Free of Disease After Receiving at Least 1 Year of Adjuvant Hormone Therapy. Participants have either: At least 4 positive lymph nodes if the patient had primary surgery At least 1 positive lymph node if surgery was conducted after neo adjuvant chemotherapy or hormone therapy of at least 3 months duration 1-3 positive lymph nodes (pN1a, b, c) at primary surgery AND EPclin Risk Score ≥3.32867 Note: Patients with EPclin Risk Score <3.32867 will not be randomized, but will be followed annually for 10 years. All patients that have been tested with EndoPredict received chemotherapy.	Primary Non-Metastatic Breast Cancer	NCT01805271	March, 2013	Learn more

Title

Summary

Indication

Protocol number

Start date

Link to ClinicalTrials.gov page

RESCUE (Reaching For Evidence-Based Chemotherapy Use In Endocrine-Sensitive Breast Cancer)

Systematic assessment of survival data of patients who have been tested with EndoPredict®; prospective proof that patients with low risk classification by EndoPredict® (EPclin) can safely forgo chemotherapy and be treated with endocrine therapy alone.

Primary Invasive Breast Cancer ER positive tumor HER2 negative tumor

NCT03503799

July 17, 2018

Learn more

UNIRAD (Safety Study of Adding *** (EVE) to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy)

Randomized, Double Blind, Multicentric Phase III Trial Evaluating the Safety and Benefit of Adding *** (EVE) to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer Who Remain Free of Disease After Receiving at Least 1 Year of Adjuvant Hormone Therapy.

Participants have either:

At least 4 positive lymph nodes if the patient had primary surgery
At least 1 positive lymph node if surgery was conducted after neo adjuvant chemotherapy or hormone therapy of at least 3 months duration
1-3 positive lymph nodes (pN1a, b, c) at primary surgery AND EPclin Risk Score ≥3.32867

Note: Patients with EPclin Risk Score <3.32867 will not be randomized, but will be followed annually for 10 years. All patients that have been tested with EndoPredict received chemotherapy.

Primary Non-Metastatic Breast Cancer

NCT01805271

March, 2013

Learn more

Clinical trials

EndoPredict® Breast Cancer Prognostic Test is actively involved in ongoing prospective clinical trials, all of which can be found on this page.

List of ongoing clinical trials

News

EndoPredict^® Breast Cancer Prognostic Test is actively involved in ongoing prospective clinical trials, all of which can be found on this page.